- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Senate passes Drug Quality and Security Act
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Roxane Labs' generic prostate drug gets tentative approval from FDA
SCHAUMBURG, Ill. — The Food and Drug Administration has approved a generic antibiotic made by Sagent Pharmaceuticals, Sagent said.
The drug maker announced the approval of clindamycin injection, which the company said was the 12th product approved under its joint venture with Strides Arcolab, under which Strides is responsible for developing and supplying injectable products that Sagent markets in the United States.
The market for injectable clindamycin this year is about $65 million, according to IMS Health.